论文部分内容阅读
目的 研究分析唑来膦酸联合辛伐他汀治疗2 型糖尿病合并骨质疏松患者的骨代谢状况.方法 收集2014 年9 月~2016 年5 月来我院就诊的177 例2 型糖尿病合并骨质疏松患者为研究对象,随机分为两组, A组的89 例病人给予唑来膦酸联合辛伐他汀治疗, B组的88 例病人给予唑来膦酸进行治疗.对比两组患者治疗前后的骨密度, 血钙(Ca) 、血磷(P) 、碱性磷酸酶(ALP) 、血清骨源性碱性磷酸酶(BAP)和血清骨钙素(OC)等各项生化指标以及治疗安全性.结果 治疗前, 两组患者各个部位的骨密度差异无统计学意义(P >0.05), 治疗后两组患者各个部位的平均骨密度均比治疗前大(P <0.05), 并且治疗后A组患者的各部位骨密度都比 B 组大(P 0.05), 治疗后两组患者的各项指标与治疗前相比, 差异有统计学意义(P <0.05), 并且治疗后A组患者的各项生化指标与B组相比差异有统计学意义(P 0.05).The average bone density after treatment was greater than that before treatment (P<0.05) and the bone density in group A was greater than that in group B (P0.05).The biochemical values after treatment were significantly different than that before treatment (P<0.05) and there were significantly differences between group A and group B (P<0.05).2 cases (2.25% ) occurred adverse reactions in group A, while 8 cases (9.09% ) in group B (χ2=3.8879, P=0.0486).Conclusion Combina-tion of zoledronic acid and simvastatin successfully inhibits bone absorption, effectively improves bone density and obviously controls the metabolism of bone in patients with type 2 diabetes mellitus and osteoporosis.